172 related articles for article (PubMed ID: 38316254)
21. Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival.
Krajewska J; Kukulska A; Oczko-Wojciechowska M; Kotecka-Blicharz A; Drosik-Rutowicz K; Haras-Gil M; Jarzab B; Handkiewicz-Junak D
Front Endocrinol (Lausanne); 2020; 11():571421. PubMed ID: 33123090
[TBL] [Abstract][Full Text] [Related]
22. Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications.
Van Nostrand D
Thyroid; 2018 Sep; 28(9):1083-1093. PubMed ID: 30105931
[TBL] [Abstract][Full Text] [Related]
23. Progress in molecular-based management of differentiated thyroid cancer.
Xing M; Haugen BR; Schlumberger M
Lancet; 2013 Mar; 381(9871):1058-69. PubMed ID: 23668556
[TBL] [Abstract][Full Text] [Related]
24. Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
Rusinek D; Chmielik E; Krajewska J; Jarzab M; Oczko-Wojciechowska M; Czarniecka A; Jarzab B
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829399
[TBL] [Abstract][Full Text] [Related]
25. Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B; Menhart K; Hellwig D; Grosse J
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629126
[TBL] [Abstract][Full Text] [Related]
26. Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.
Tumino D; Frasca F; Newbold K
Front Endocrinol (Lausanne); 2017; 8():312. PubMed ID: 29209273
[TBL] [Abstract][Full Text] [Related]
27. Extent of Surgery for Low-Risk Differentiated Thyroid Cancer.
McDow AD; Pitt SC
Surg Clin North Am; 2019 Aug; 99(4):599-610. PubMed ID: 31255194
[TBL] [Abstract][Full Text] [Related]
28. [Draft of the best medical treatment in patients with low-risk thyroid cancer].
Vlček P; Nováková D; Vejvalka J; Zimák J; Křenek M; Vošmiková K; Smutný S; Bavor P; Astl J; Lukáš J
Vnitr Lek; 2015 Sep; 61(9):769-77. PubMed ID: 26465275
[TBL] [Abstract][Full Text] [Related]
29. Key data from the 2023 European Thyroid Association annual meeting: De-escalation strategy in diagnosis and the treatment of differentiated thyroid carcinoma: Update after the 2023 ETA congress.
Haissaguerre M; Lamartina L; Caron P
Ann Endocrinol (Paris); 2024 Apr; 85(2):155-157. PubMed ID: 38336563
[No Abstract] [Full Text] [Related]
30. Recurrent Differentiated Thyroid Cancer: The Current Treatment Options.
Coca-Pelaz A; Rodrigo JP; Shah JP; Nixon IJ; Hartl DM; Robbins KT; Kowalski LP; Mäkitie AA; Hamoir M; López F; Saba NF; Nuyts S; Rinaldo A; Ferlito A
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345029
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of differentiated thyroid cancers of nodular type].
Tourniaire J; Bernard MH; Bertholon-Gregoire M; Adeleine P; Berger-Dutrieux N
Ann Endocrinol (Paris); 1997; 58(3):211-5. PubMed ID: 9239243
[TBL] [Abstract][Full Text] [Related]
32. Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma: A Qualitative Study.
Nickel B; Brito JP; Barratt A; Jordan S; Moynihan R; McCaffery K
Thyroid; 2017 May; 27(5):661-671. PubMed ID: 28322617
[TBL] [Abstract][Full Text] [Related]
33. Advancements in the treatment of differentiated thyroid cancer.
Stewart LA; Kuo JH
Ther Adv Endocrinol Metab; 2021; 12():20420188211000251. PubMed ID: 33796254
[TBL] [Abstract][Full Text] [Related]
34. [Radioiodine therapy and radioiodine after-care in differentiated thyroid gland carcinomas].
Börner AR; Müller-Gärtner HW
Zentralbl Chir; 1997; 122(4):274-85. PubMed ID: 9221638
[TBL] [Abstract][Full Text] [Related]
35. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
36. Radioiodine Refractory Differentiated Thyroid Cancer.
Chan WWL; Chan S; Kwong DLW
Methods Mol Biol; 2022; 2534():243-257. PubMed ID: 35670980
[TBL] [Abstract][Full Text] [Related]
37. Current practice in intermediate risk differentiated thyroid cancer - a review.
do Prado Padovani R; Duarte FB; Nascimento C
Rev Endocr Metab Disord; 2024 Feb; 25(1):95-108. PubMed ID: 37995023
[TBL] [Abstract][Full Text] [Related]
38. 'Aggressive papillary' thyroid microcarcinoma.
Page C; Biet A; Boute P; Cuvelier P; Strunski V
Eur Arch Otorhinolaryngol; 2009 Dec; 266(12):1959-63. PubMed ID: 19294400
[TBL] [Abstract][Full Text] [Related]
39. Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy.
Hong CM; Ahn BC
Front Endocrinol (Lausanne); 2017; 8():260. PubMed ID: 29085335
[TBL] [Abstract][Full Text] [Related]
40. [The course of differentiated thyroid microcarcinoma in patients treated by different therapeutic strategies].
Grigerová M; Griger M; Mojtová E; Podoba J
Vnitr Lek; 2016; 62(9 Suppl 3):17-21. PubMed ID: 27734686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
